Lv51
1129 积分 2024-07-03 加入
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
16分钟前
求助中
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1小时前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
5天前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
5天前
已完结
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
7天前
已完结
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
8天前
已完结
Chinese expert consensus on the diagnosis and treatment of mixed hyperlipidemia in primary care (2024)
10天前
已完结
[Clinical practice guidelines for the management of hypertension in China]
10天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
20天前
已完结
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
20天前
已完结
A game theoretic approach for analyzing financial intervention models in dairy green supply chains with freshness-keeping effort
Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients
皖公网安备34019202002308
